Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) can lead to non‐alcoholic steatohepatitis (NASH) and cirrhosis. Fibrosis predicts worse outcomes and mortality. New treatments targeting fibrosis are being investigated to reverse disease progression. Aim: To review the new pipeline therapeutic agents targeting fibrosis in NASH patients, with particular focus on clinical trials in which reversing fibrosis and portal hypertension are the primary outcomes. Methods: The literature was searched in PubMed between January 2000 and January 2016 using search terms non‐alcoholic fatty liver disease and NASH, with filters of ‘English language’. We focused on fibrosis improvement as the key outcome. We also searched the ClinicalTrials.gov for promising agents that target fibrosis in NASH patients. Results: Significant advances have been made on approaches targeting fibrosis in NASH patients. Many therapeutic agents are already in development, some of which have shown promising results in preclinical and phase I studies. Novel therapies have entered phase II and III studies targeting fibrosis reversal and/or improvement in portal hypertension. Innovative studies have also started looking into combining these agents, aiming at different mechanisms to maximise therapeutic outcomes. We found five clinical trials in phase II and one in phase III focusing on fibrosis in NASH patients as key outcomes. One of the phase II trials is using combination therapy to target fibrosis. Conclusions: Ongoing research studies are already investigating new pathways aimed at reversing fibrosis in NASH patients. Novel therapeutic agents are in development and are expected to offer unique options to NASH patients with advanced fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationHuman Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“Pioglitazone has been shown to reduce liver fat content and liver enzymes and improve histology.(109) However, as mentioned above, the PIVEN trial that compared treatment of vitamin E with pioglitazone and placebo showed that vitamin E therapy was associated with a higher rate”
ResultMarcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“which is the natural agonist of the farnesoid X receptor, a nuclear hormone receptor that regulates glucose and lipid metabolism.(73) OCA is an approximately 100-fold more potent activator of the farnesoid X nuclear receptor than CDCA.”
BackgroundBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 1×
“overactivation of TLR signalling and breakdown of TLR tolerance, with increased production of inflammatory cytokines leading to tissue injury.(54) In mouse models, (i) a direct link has been established between TLR4 and the Kupffer cells responsible for clearing endotoxin in”
BackgroundRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“lation and inhibit proinflammatory (IL-1b, TNF-a and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression.(128)”
BackgroundD'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., Colombo, M., & Bedossa, P. (2012) · Hepatology · doi:10.1002/hep.25606 · Cited by 409
Kempf, K., Herder, C., Erlund, I., Kolb, H., Martin, S., Carstensen, M., Koenig, W., Sundvall, J., Bidel, S., Kuha, S., et al. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28548 · Cited by 364
Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults
Campbell, P. T., Newton, C. C., Patel, A. V., Jacobs, E. J., & Gapstur, S. M. (2012) · Diabetes Care · doi:10.2337/dc12-0002 · Cited by 339
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318 · cited 1×
“A pooled meta-analysis specifically focusing on pioglitazone suggests that pioglitazone may improve fibrosis.(64)”
BackgroundSelf-citationTomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., Okada, Y., Kurihara, C., Irie, R., Yokoyama, H., et al. (2014) · Hepatology · doi:10.1002/hep.26604 · Cited by 315
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9
Watanabe, A., Hashmi, A., Gomes, D. A., Town, T., Badou, A., Flavell, R. A., & Mehal, W. Z. (2007) · Hepatology · doi:10.1002/hep.21867 · Cited by 262
Teratani, T., Tomita, K., Suzuki, T., Oshikawa, T., Yokoyama, H., Shimamura, K., Tominaga, S., Hiroi, S., Irie, R., Okada, Y., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.049 · Cited by 241
Dietary glycotoxins exacerbate progression of experimental fatty liver disease
Leung, C., Herath, C. B., Jia, Z., Goodwin, M., Mak, K. Y., Watt, M. J., Forbes, J. M., & Angus, P. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.033 · Cited by 88
Jiang, J. X., Chen, X., Fukada, H., Serizawa, N., Devaraj, S., & Török, N. J. (2013) · Hepatology · doi:10.1002/hep.26491 · Cited by 49 · cited 1×
“in1/Timp3, the combination of which leads to HSC activation and fibrogenesis.(51) These dietary effects in mice”
Background
Cited by
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
“These data are of importance in clinical trials studying novel therapies aimed at reducing fibrosis progression and disease-specific complications((14)) and in clinical practice where a patient-specific risk profile can be generated to help guide personalized treatment decisions.”
BackgroundSelf-citationDella Corte, C., Carpino, G., De Vito, R., De Stefanis, C., Alisi, A., Cianfarani, S., Overi, D., Mosca, A., Stronati, L., Cucchiara, S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168216 · Cited by 112
Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.008 · Cited by 48
Metadata
- Authors
- Noureddin, M., Anstee, Q. M., & Loomba, R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-04-08
- Volume
- 43
- Issue
- 11
- Pages
- 1109-1123
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2329054607
- Cited by
- 51
- References
- 29
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.